Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Magnetic imaging agent
Reexamination Certificate
2007-06-12
2007-06-12
Hartley, Michael G. (Department: 1618)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Magnetic imaging agent
C424S009364, C424S009365, C424S009360, C424S009300
Reexamination Certificate
active
10755507
ABSTRACT:
The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.
REFERENCES:
patent: 3632637 (1972-01-01), Martell
patent: 4150047 (1979-04-01), Coe et al.
patent: 4308249 (1981-12-01), Frank et al.
patent: 4331647 (1982-05-01), Goldenberg
patent: 4352751 (1982-10-01), Wieder et al.
patent: 4361544 (1982-11-01), Goldenberg
patent: 4401647 (1983-08-01), Krohn et al.
patent: 4472509 (1984-09-01), Gansow et al.
patent: 4615879 (1986-10-01), Runge et al.
patent: 4639365 (1987-01-01), Sherry
patent: 4647447 (1987-03-01), Gries et al.
patent: 4687658 (1987-08-01), Quay
patent: 4714607 (1987-12-01), Klaveness
patent: 4746507 (1988-05-01), Quay
patent: 4834964 (1989-05-01), Rosen
patent: 4859451 (1989-08-01), Quay et al.
patent: 4880008 (1989-11-01), Lauffer
patent: 4885363 (1989-12-01), Tweedle et al.
patent: 4899755 (1990-02-01), Lauffer et al.
patent: 4957939 (1990-09-01), Gries et al.
patent: 4963344 (1990-10-01), Gries et al.
patent: 4980502 (1990-12-01), Felder et al.
patent: 5017359 (1991-05-01), Nicolau et al.
patent: 5078986 (1992-01-01), Bosworth et al.
patent: 5091169 (1992-02-01), Rocklage et al.
patent: 5094848 (1992-03-01), Brixner
patent: 5223243 (1993-06-01), Rocklage et al.
patent: 5250285 (1993-10-01), Lauffer et al.
patent: 5314679 (1994-05-01), Lewis et al.
patent: 5318769 (1994-06-01), Bacon et al.
patent: 5318771 (1994-06-01), Lauffer et al.
patent: 5358704 (1994-10-01), Desreux et al.
patent: 5362475 (1994-11-01), Gries et al.
patent: 5380519 (1995-01-01), Schneider et al.
patent: 5385719 (1995-01-01), Unger et al.
patent: 5407659 (1995-04-01), Deutsch et al.
patent: 5474756 (1995-12-01), Tweedle et al.
patent: 5487390 (1996-01-01), Cohen et al.
patent: 5505932 (1996-04-01), Grinstaff et al.
patent: 5512332 (1996-04-01), Liberti et al.
patent: 5525338 (1996-06-01), Goldenberg
patent: 5545395 (1996-08-01), Tournier et al.
patent: 5573752 (1996-11-01), Ranganathan et al.
patent: 5635180 (1997-06-01), Morgan, Jr. et al.
patent: 5649537 (1997-07-01), Anelli et al.
patent: 5660814 (1997-08-01), Uggeri et al.
patent: 5674470 (1997-10-01), Tweedle et al.
patent: 5725840 (1998-03-01), Klaveness et al.
patent: 5846519 (1998-12-01), Tweedle et al.
patent: 6307074 (2001-10-01), Brocchetta et al.
patent: 6342598 (2002-01-01), Anelli et al.
patent: 6461588 (2002-10-01), Anelli et al.
patent: 6479681 (2002-11-01), Brocchetta et al.
patent: 6652834 (2003-11-01), Anelli et al.
patent: 6652835 (2003-11-01), Lauffer et al.
patent: 8633082 (1983-01-01), None
patent: 2139374 (1995-07-01), None
patent: 2606721 (1976-09-01), None
patent: 3129906 (1983-02-01), None
patent: 3401052 (1984-07-01), None
patent: 0450742 (1991-10-01), None
patent: 0133603 (1985-02-01), None
patent: 0165728 (1985-12-01), None
patent: 0230893 (1987-08-01), None
patent: 0232751 (1987-08-01), None
patent: 0250358 (1987-12-01), None
patent: 0258616 (1988-03-01), None
patent: 0290041 (1988-11-01), None
patent: 0290047 (1988-11-01), None
patent: 0292689 (1988-11-01), None
patent: 0292761 (1988-11-01), None
patent: 0304780 (1989-03-01), None
patent: 0331616 (1989-09-01), None
patent: 0347947 (1989-12-01), None
patent: 0169299 (1990-04-01), None
patent: 0374947 (1990-06-01), None
patent: 0405704 (1991-01-01), None
patent: 0454078 (1991-10-01), None
patent: 0455380 (1991-11-01), None
patent: 0463644 (1992-01-01), None
patent: 0485045 (1992-05-01), None
patent: 0535668 (1993-04-01), None
patent: 0543482 (1993-05-01), None
patent: 0661279 (1995-07-01), None
patent: 0 279 307 (1996-11-01), None
patent: 2354993 (1978-01-01), None
patent: 2643370 (1990-08-01), None
patent: WO 85/02772 (1985-07-01), None
patent: WO 85/05554 (1985-12-01), None
patent: WO 86/01410 (1986-03-01), None
patent: WO 86/02005 (1986-04-01), None
patent: WO 86/02352 (1986-04-01), None
patent: WO 86/02841 (1986-05-01), None
patent: WO 86/06605 (1986-11-01), None
patent: WO 88/07521 (1988-10-01), None
patent: WO 89/01475 (1989-02-01), None
patent: WO 89/01476 (1989-02-01), None
patent: WO 89/12631 (1989-12-01), None
patent: WO 90/03804 (1990-04-01), None
patent: WO 91/03200 (1991-03-01), None
patent: WO 91/18630 (1991-12-01), None
patent: WO 93/03351 (1993-02-01), None
patent: WO 95/15306 (1995-06-01), None
patent: WO 95/28392 (1995-10-01), None
patent: WO 95/32741 (1995-12-01), None
patent: WO 98/05625 (1998-12-01), None
patent: WO 00/38738 (2000-07-01), None
Pratt and Taylor (eds.), “The Binding of Drugs to Plasma Proteins,”Principles of Drug Action. The Basis of Pharmacology,1990, Third Edition, Churchill Livingstone, pp. 231-236.
“Phenolic derivatives of (hydroxyalkyl)alky=lenediamineacetic acids and their salts”,Chemical Abstracts,89, p. 561, Abstract No. 215057x (1978).
Bagley et al., “Distribution of Intravenously Administered Ferrioxamine-59 and Ferric N,N′-Ethylenebis (α Imino-2-Hydroxy-5-Chlorophenylacetate) in Rats”,Proc. Soc. Exptl. Biol. Med.,127, pp. 798-801 (1968).
Barnhart et al., “Is there Stereospecificity in Hepatic Uptake of Phenyl-derivatized Contrast Agents?”,Contrast Media Research,(Oct. 1993).
Best et al., “Chemical and In Vivo Characterization of Gd-bis-Phenylalanyl DTPA Derivatives: A Class of Hepatobiliary MRI Contrast Agents”,Proc. Soc. Magnetic Resonance, Second Meeting,v1, p. 264 (Aug. 1994).
Bogdanov et al., “A New Macromolecule as a Contrast Agent for MR Angiography: Preparation, Properties, and Animal Studies”,Radiology,187, pp. 701-706 (1993).
Brasch et al., “Contrast-Enhanced NMR Imaging: Animal Studies Using Gadolinium-DTPA Complex,”AJR,142, pp. 625-630 (1984).
Brittain et al., “Luminescence and NMR Studies of the Conformational Isomers of Lanthanide Complexes with an Optically Active Polyaza Polycarboxylic Macrocycle”,Inorg. Chem.,23, pp. 4459-4466 (1984).
Caravan et al., “Gandolinium (III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications”,Chem. Rev.,99, pp. 2293-2352 (1999).
Carter et al., “Structure of Serum Albumin”,Adv. Protein Chem.,45, pp. 153-203 (1994).
Chen et al., “Paramagnetic Metalloporphyrins as Potential Contrast Agents in NMR Imaging”,FEBS Letters,168, pp. 70-74 (1984).
Chu, “The Quantitative Analysis of Structure-Activity Relationships”, Burger's Medicinal Chemistry, Part 1, pp. 393-418 (4thEd., 1980).
Davison, “Protein Binding”,Fundamentals of Drug Metabolism and Drug Disposition,La Du et al., eds., pp. 63-75, R.E. Krieger Pub. Co. (1971).
Desreux et al., “Nuclear Magnetic Resonance Spectroscopy of Lanthanide Complexes with a Tetraacetic Tetraaza Macrocycle. Unusual Conformation Properties”,Inorg. Chem.,19, pp. 1319-1324 (1980).
Felix et al., “Brain Tumors: MR Imaging with Gadolinium-DTPA”,Radiology,156, pp. 681-688 (1985).
Goldstein, “The Interactions of Drugs and Plasma Proteins,”Pharm. Rev.,1949, 1:102-165.
Graf et al., “Iron-catalyzed Hydroxyl Radical Formation”,J. Biol. Chem.,259, pp. 3620-3624 (1984).
Haddock et al., “Biliary Excretion of Chelated Iron”,Proc. Soc. Exptl. Biol. Med.,120, pp. 663-668 (1965).
Harrison et al., “Hepato-biliary and Renal Excretion in Mice of Charged and Neutral Gadolinium Complexes of Cyclic Tetra-aza-phosphinic and Carboxylic Acids”,Magn. Res. Imaging,11, pp. 761-770 (1993).
He et al., “Atomic Structure and Chemistry of Human Serum Albumin”,Nature,358, pp. 209-215 (1992).
Hoey et al., “Chemistry of X-Ray Contrast Media”,Radiocontrast Agents,Sovak, ed., Springer-Verlag, pp. 23-125 (1984).
K
Lauffer Randall B.
McMurry Thomas J.
Scott Daniel M.
Sijiki Hironao
Epix Pharmaceuticals Inc.
Fish & Richardson P.C.
Hartley Michael G.
Schlientz Leah
LandOfFree
Diagnostic imaging contrast agents with extended blood... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnostic imaging contrast agents with extended blood..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostic imaging contrast agents with extended blood... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3810183